European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 61.12 -0.56 (0.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.68 | 52 Week High | $77.12 | |||
| Open | $61.50 | 52 Week Low | $49.03 | |||
| Day High | $61.81 | P/E | 39.69 | |||
| Day Low | $60.69 | EPS | $1.54 | |||
| Volume | 9,016,252 | |||||
